Back to Search
Start Over
Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing
- Source :
- Transplantation reviews (Orlando, Fla.). 26(4)
- Publication Year :
- 2011
-
Abstract
- Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) formulation, has improved both short- and long-term outcomes following renal transplantation, but is often associated with gastrointestinal (GI) complications that can lead to dose reduction or discontinuation, potentially jeopardizing patient outcomes. Enteric-coated mycophenolate sodium (EC-MPS) delivers equivalent MPA exposure to MMF and offers the potential to reduce GI burden (while maintaining patient safety). Here we review the efficacy of EC-MPS compared with MMF in renal transplant patients in terms of biopsy-proven acute rejection and graft loss, and examine the use of EC-MPS in newer regimens such as intensified dosing and calcineurin inhibitor minimization.
- Subjects :
- Graft Rejection
Transplantation
medicine.medical_specialty
business.industry
medicine.medical_treatment
Urology
Mycophenolate Sodium
Immunosuppression
Pharmacology
Mycophenolic Acid
medicine.disease
Mycophenolate
Kidney Transplantation
Mycophenolic acid
Calcineurin
medicine
Humans
Dosing
Tablets, Enteric-Coated
business
Kidney transplantation
Immunosuppressive Agents
medicine.drug
Subjects
Details
- ISSN :
- 15579816
- Volume :
- 26
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Transplantation reviews (Orlando, Fla.)
- Accession number :
- edsair.doi.dedup.....55038ca78cbe772a98ee83feea7654f7